Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-440 + Tezacaftor/Ivacaftor in Healthy Adults
NCT03486236Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ivacaftor in cystic fibrosis (CF) (4 cohorts), sponsored by Vertex Pharmaceuticals. Primary endpoint: Number and assessment of adverse events and serious adverse events at 29 days. Started Jul 2016; status: completed.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03486236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03486236.